Navigation Links
Exelixis Commences Public Offering of Common Stock
Date:9/10/2007

SOUTH SAN FRANCISCO, Calif., Sept. 10 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that it has agreed to sell 7,000,000 shares of its common stock pursuant to an effective automatic shelf registration statement. Exelixis will also grant the underwriter a 30-day option to purchase up to an additional 1,050,000 shares of common stock. All of the shares in the offering will be sold by Exelixis. Goldman, Sachs & Co. is acting as the sole underwriter for the offering. Closing of the offering is expected to occur on or about September 13, 2007, subject to customary closing conditions.

The offering is being made pursuant to an effective automatic shelf registration statement. The offering may be made only by means of a prospectus supplement and the accompanying prospectus, copies of which may be obtained by sending a request to: Goldman, Sachs & Co., Attn: Prospectus Department, 85 Broad Street, New York, New York 10004, Fax: 212-902-9316 or Email at prospectus-ny@ny.email.gs.com.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any of the securities, nor shall there be any sale of these securities, in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Safe Harbor Statement

This press release contains forward-looking statements. Words such as "expects," "intends" and similar expressions are intended to identify forward- looking statements. These forward-looking statements are based upon Exelixis' current expectations. Forward-looking statements involve risks and uncertainties. Exelixis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties related to satisfaction of customary closing conditions related to the public offering. There can be no assurance that Exelixis will complete the offering of the common stock on the anticipated terms, or at all. In addition, Exelixis' business is subject to the risks detailed in Exelixis' filings with the Securities and Exchange Commission. Exelixis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Exelixis and the Exelixis logo are registered U.S. trademarks.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Pfizer Commences Its Advertising for Celebrex with All the Warnings
2. Natco Pharma Commences Production At Dehradun Unit
3. Chinas First Gay Health Clinic Commences Operations
4. Mental Health - NHS Trust Commences Specialist Transition Service
5. Surface Logix Commences Phase 2a Clinical Trial of SLx-2101 in Raynauds Disease
6. Trial of VivaGel in Sexually Active Young Women Commences
7. Controversial deal on public access of the human genome map
8. Defibrillators In Public Places Will Help Cardiac Patients
9. WHO To Support Public Health Threats
10. Public Defibrillators Found To Improve Survival Rate
11. FDA Issues Public Health Advisory on Tysabri, a New Drug for MS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... Dalton, GA (PRWEB) , ... July 21, 2017 ... ... provides asset protection and financial consultation services to families and business owners in ... charity drive to raise support for children overcoming sexual assault and physical abuse. ...
(Date:7/21/2017)... Minnesota (PRWEB) , ... July 21, 2017 , ... ... BWBR recently were selected to renovate and improve the Ramsey County Medical Examiners ... adjacent to Regions Hospital, the $2.5 million project is scheduled to start in ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Margarian Law Firm has filed a ... ginger ale for allegedly containing no ginger. Dr. Pepper produces the “Canada Dry” brand ... Gegham Margaryan alleges Canada Dry Ginger Ale claims on its bottle that it is ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... Tears® EyeMist®, the signature product of her research center at Bio-Logic Aqua Research® ... largest population and the greatest number of sufferers of blindness. “We think that ...
(Date:7/20/2017)... ... July 20, 2017 , ... TransPixel Volume 2 is a set of ... FCPX timeline. This effect isolates horizontal and vertical lines of pixels and sorts their ... rotating or flipping animation and can be changed using a drop-down menu. Create amazing ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... -- RK Logistics Group, Inc. was awarded California ... Fremont, CA headquarters facility where it provides ... San Jose for hi-tech, pharmaceutical and biomedical ... with its Fremont Innovation District, is excited to strategically partner ... to the hundreds of biotech, pharma and biomed companies throughout ...
(Date:7/11/2017)... Research Corp., also known as ,The Epigenetics Company, announced today the release ... manner using the myDNAge ™ test. Based on Horvath,s Clock, so ... and biostatistics at the David Geffen School of Medicine at UCLA ... DNAge ™ technology is used to analyze DNA methylation patterns of ... ...
(Date:7/11/2017)... Fla. , July 11, 2017  Dr. Echenberg, founder of Echenberg ... therapy program to patients who suffer from painful intercourse and other painful ... and vaginal atrophy due to menopause. ... VuVatech LLC ... , created by Sarasota, Florida -based start-up company, VuVatech ...
Breaking Medicine Technology: